Diagnostic and Treatment Approaches for Pulmonary Embolism and Acute Coronary Syndrome

Diagnostic Differences

The European Society of Cardiology recommends stratifying patients with suspected Pulmonary Embolism (PE) based on hemodynamic stability, with high-risk PE requiring immediate anticoagulation and potential reperfusion therapy 1, 2, 3, 4
For patients with suspected PE, the European Heart Journal suggests assessing clinical probability using validated prediction rules, measuring D-dimer in low/intermediate probability patients, and proceeding to CTPA if D-dimer positive or high clinical probability 2, 3, 4
The American College of Cardiology recommends ECG as the initial test of choice for suspected Acute Coronary Syndrome (ACS), with cardiac biomarkers and coronary angiography often needed for definitive diagnosis 1, 2, 3

The European Society of Cardiology recommends immediate systemic thrombolytic therapy for high-risk PE, with surgical pulmonary embolectomy if thrombolysis is contraindicated or fails 1, 4
For non-high-risk PE, the European Heart Journal suggests anticoagulation with preference for LMWH or fondaparinux over UFH, and oral anticoagulation with NOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) 4
The American College of Cardiology recommends antiplatelet therapy, anticoagulation, and reperfusion therapy for ACS, with beta-blockers, statins, and ACE inhibitors also recommended 2, 3

The European Society of Cardiology recommends therapeutic anticoagulation for >3 months for all patients with PE, with consideration of discontinuation after 3 months for first PE with transient risk factor 4
For ACS, the American College of Cardiology recommends dual antiplatelet therapy, secondary prevention with statins, beta-blockers, and ACE inhibitors, and lifestyle modifications and risk factor control 2, 3

The European Heart Journal suggests considering PE in patients with suspected ACS but normal coronary angiogram, and using validated diagnostic methods for suspected PE during pregnancy 4
The American College of Cardiology recommends administering therapeutic, fixed doses of LMWH based on early pregnancy weight, and avoiding NOACs during pregnancy or lactation 4